Claims for Patent: 9,133,236

Summary for Patent: 9,133,236

Title:	Connective tissue stimulating peptides
Abstract:	Novel peptides are described which comprise an amino acid motif selected from the group consisting of \"PG\", \"GP\", \"PI\" and \"IG\" and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein \"P\" in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.
Inventor(s):	Sindrey; Dennis R. (Oakville, CA), Pugh; Sydney M. (Glenburnie, CA), Smith; Timothy J. N. (Kingston, CA)
Assignee:
Application Number:	12/378,591
Patent Claims:	1. A peptide comprising an amino acid motif selected from the group consisting of "GPI", "LPG", "GLP", "PIG" and "IGP" and having up to 10 amino acids upstream and/or downstream of said amino acid motif, wherein "P" in said motif is proline or hydroxyproline (P*), wherein the peptide is bound to a carrier such that when the peptide and the carrier are implanted into a body in the vicinity of bone, cartilage and/or associated connective tissue, the peptide is released to the bone, cartilage and/or associated connective tissue in a controlled and sustained manner in a therapeutically effective amount for a period of time greater than 24 hours in order to stimulate the development, maintenance and repair of the bone, cartilage and/or associated connective tissue; wherein the carrier comprises SKELITE.TM.; and further wherein the peptide is selected from the group consisting of NGLPGPIGP* (SEQ. ID. NO. 1); NGLPGPIG (SEQ. ID. NO.2); NGLP*GPIG (SEQ. ID. NO.3); NGLP*GPIGP* (SEQ. ID.NO.4); NGLPGP (SEQ ID.NO.5); LPGP (SEQ.ID.NO.6); PGPIG (SEQ ID.NO.7); NGLPGPIGP (SEQ.ID.NO.8); PGPIGP (SEQ ID.NO.9); PGPIGPPGPR (SEQ.ID.NO.10); GPIG (SEQ.ID.NO.11); PGPIGPPGPRGRTGDA (SEQ.ID.NO.12); GPRGRTGDA (SEQ.ID.NO.13); PGPIGPP (SEQ.ID.NO.14); PGPIGP* (SEQ.ID.NO.15); PGPI (SEQ.ID.NO.16); GLPGPIG (SEQ.ID.NO.17); GPIGP* (SEQ.ID.NO.18); GPIGP (SEQ.ID.NO.19); PIGP (SEQ.ID.NO.20) and mixtures thereof. 2. The peptide of claim 1, wherein said peptide stimulates the activity of bone cells, bone cell precursors and cells sharing lineage. 3. The peptide of claim 1, wherein said peptide stimulates the activity of cartilage cells, cartilage cell precursors and cells sharing lineage. 4. The peptide of claim 1, wherein said peptide stimulates the formation of bone. 5. The peptide of claim 1, wherein said peptide stimulates the formation of cartilage. 6. The peptide of claim 1, wherein said peptide stimulates a response in vitro, ex vivo and/or in vivo. 7. The peptide of claim 6, wherein said peptide is at least four amino acids in length. 8. The peptide of claim 1, wherein "P" is hydroxyproline. 9. The peptide of claim 6, wherein said peptide further comprises one or more linker groups. 10. The peptide of claim 9, wherein said linker group is selected from the group consisting of carbodiimide, aldehyde, maleimide, sulfhydryl, amino, carboxy, hydroxy and NHS esters, a modified cysteine, a phosphorylated amino acid, an amino acid, diacetic acid, sulfonyl chloride, isocyanate, isothiocyanate, epoxy, bisphosphonate, pyrophosphate, phosphate, disulfide, phenyl azide, alkyl halide and hydrazide acyl chloride. 11. The peptide of claim 1, wherein said peptide is provided as a chimeric protein. 12. The peptide of claim 11, wherein said chimeric protein comprises a calcium binding sequence of a protein selected from the group consisting of osteopontin, dentine matrix phosphoprotein, phosvitin, phosphohoryn, beta-casein, stratherin, matrix gla protein, riboflavin binding protein and alpha S1 casein. 13. The peptide of claim 12, wherein said binding sequence is selected from the group consisting of S*S*, S*S*GS*EE, S*S*S*EE, S*S*S*S*S*S*, DS*S*DS*S*, S*LS*S*S*S*, DS*S*EE, DS*S*ES*, S*MS*S*S*EE and S*IS*S*S*EE and combinations thereof, wherein S* denotes a phosphorylated serine amino acid residue. 14. The peptide of claim 1, wherein said stimulation may be assessed by the analysis of one or more criteria selected from the group consisting of bone mineral density, bone mineral content, alkaline phosphatase activity, proliferation of osteoblasts, bone nodule formation, bone nodule mineralization, chondrocyte proliferation, intracellular calcium channeling assay, collagen assay and proteoglycan assay. 15. The peptide of claim 1, wherein said peptide is provided as a composition with a pharmaceutically acceptable carrier. 16. The peptide of claim 15, wherein said composition further comprises an agent selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, fibrin, hyaluronic acid, proteoglycans, calcitonin, estrogen, estradiol, prostaglandin Al, bisphosphonic acids, ipriflavones, sodium fluoride, vitamin K, bone morphogenetic proteins, fibroblast growth factor, platelet-derived growth factor, transforming growth factor, insulin-like growth factors 1 and 2, endothelin, parathyroid hormone, epidermal growth factor, leukemia inhibitory factor, osteogenin and mixtures thereof. 17. The peptide of claim 15, wherein said composition may be administered locally and/or systemically. 18. The peptide of claim 17, wherein systemic administration is selected from intravenous injection, intramuscular injection, intraperitoneal injection, oral administration, enteral administration, parenteral administration, intranasal administration, pulmonary administration, topical administration, transdermal administration and combinations thereof. 19. The peptide of claim 17, wherein local administration is provided by injection or use with an implant. 20. The peptide of claim 19, wherein said peptide is provided as a coating, filling or dispersed within a matrix of said implant. 21. The peptide of claim 20, wherein said peptide is provided with a granular or powdered biomaterial compound. 22. The peptide of claim 1, wherein said peptide is provided with a biocompatible and/or biodegradable polymer. 23. The peptide of claim 1, wherein the peptide has the sequence NGLPGPIGP* (SEQ. ID. NO.1). 24. The peptide of claim 23, wherein the peptide further comprises S*S*S*EE. 25. The peptide of claim 1, wherein the peptide has the sequence PGPIG (SEQ ID.NO.7). 26. The peptide of claim 1, wherein the peptide has the sequence GPIG (SEQ.ID.NO.11). 27. The peptide of claim 1, wherein the peptide has the sequence PGPIGP* (SEQ.ID.NO.15). 28. The peptide of claim 1, wherein the peptide has the sequence PGPIGPPGPRGRTGDA (SEQ.ID.NO.12). 29. A composition for the stimulation of the development, maintenance and repair of bone, cartilage and related connective tissues, the composition comprising: a peptide comprising an amino acid motif selected from the group consisting of "GPI", "LPG", "GLP", "PIG" and "IGP" and having up to 10 amino acids upstream and/or downstream of said amino acid motif, wherein "P" in said motif is proline or hydroxyproline; wherein the peptide is selected from the group consisting of NGLPGPIGP* (SEQ. ID. NO. 1); NGLPGPIG (SEQ. ID. NO.2); NGLP*GPIG (SEQ. ID. NO.3); NGLP*GPIGP* (SEQ. ID.NO.4); NGLPGP (SEQ ID.NO.5); LPGP (SEQ.ID.NO.6); PGPIG (SEQ ID.NO.7); NGLPGPIGP (SEQ.ID.NO.8); PGPIGP (SEQ ID.NO.9); PGPIGPPGPR (SEQ.ID.NO.10); GPIG (SEQ.ID.NO.11); PGPIGPPGPRGRTGDA (SEQ.ID.NO.12); GPRGRTGDA (SEQ.ID.NO.13); PGPIGPP (SEQ.ID.NO.14); PGPIGP* (SEQ.ID.NO.15); PGPI (SEQ.ID.NO.16); GLPGPIG (SEQ.ID.NO.17); GPIGP* (SEQ.ID.NO.18); GPIGP (SEQ.ID.NO.19); PIGP (SEQ.ID.NO.20) and mixtures thereof; and a pharmaceutically acceptable carrier bound to the peptide such that when the peptide and the pharmaceutically acceptable carrier are implanted into a body in the vicinity of bone, cartilage and related connective tissues, the peptide is released to the bone, cartilage and related connective tissues in a controlled and sustained manner in a therapeutically effective amount for a period of time greater than 24 hours in order to stimulate the development, maintenance and repair of the bone, cartilage and related connective tissues, wherein the carrier comprises SKELITE.TM.. 30. The composition of claim 29, wherein said composition further comprises an agent selected from the group consisting of calcium phosphate, calcium sulfate, calcium carbonate, fibrin, hyaluronic acid, proteoglycans, calcitonin, estrogen, estradiol, prostaglandin Al, bisphosphonic acids, ipriflavones, sodium fluoride, vitamin K, bone morphogenetic proteins, fibroblast growth factor, platelet-derived growth factor, transforming growth factor, insulin-like growth factors 1 and 2, endothelin, parathyroid hormone, epidermal growth factor, leukemia inhibitory factor, osteogenin and mixtures thereof. 31. The composition of claim 29, wherein said composition is for local and/or systemic administration. 32. The composition of claim 31, wherein systemic administration is selected from intravenous injection, intramuscular injection, intraperitoneal injection, oral administration, enteral administration, parenteral administration, intranasal administration, pulmonary administration, topical administration, transdermal administration and combinations thereof. 33. The composition of claim 31, wherein local administration is provided by injection or use with an implant. 34. The composition of claim 33, wherein said composition is provided as a coating, filling or dispersed within a matrix of said implant. 35. The composition of claim 34, wherein said composition is provided with a granular or powdered biomaterial compound. 36. The composition of claim 29, wherein said composition is provided with a biocompatible and/or biodegradable polymer. 37. A method for stimulating the development, maintenance and repair of bone, cartilage and associated connective tissue in a mammal, the method comprising administering an effective amount of a peptide comprising an amino acid motif selected from the group consisting of "GPI", "PGP", "LPG", "GLP", "PIG", and "IGP" and having up to 10 amino acids upstream and/or downstream of said amino acid motif, wherein "P" in said motif is proline or hydroxyproline, wherein the peptide is bound to a carrier such that when the peptide and the carrier are implanted into a body in the vicinity of bone, cartilage and/or associated connective tissue, the peptide is released to the bone, cartilage and/or associated connective tissue in a controlled and sustained manner in a therapeutically effective amount for a period of time greater than 24 hours in order to stimulate the development, maintenance and repair of the bone, cartilage and/or associated connective tissue; wherein the carrier comprises SKELITE.TM.; and further wherein the peptide is selected from the group consisting of NGLPGPIGP* (SEQ. ID. NO. 1); NGLPGPIG (SEQ. ID. NO.2); NGLP*GPIG (SEQ. ID. NO.3); NGLP*GPIGP* (SEQ. ID.NO.4); NGLPGP (SEQ ID.NO.5); LPGP (SEQ.ID.NO.6); PGPIG (SEQ ID.NO.7); NGLPGPIGP (SEQ.ID.NO.8); PGPIGP (SEQ ID.NO.9); PGPIGPPGPR (SEQ.ID.NO.10); GPIG (SEQ.ID.NO.11); PGPIGPPGPRGRTGDA (SEQ.ID.NO.12); GPRGRTGDA (SEQ.ID.NO.13); PGPIGPP (SEQ.ID.NO.14); PGPIGP* (SEQ.ID.NO.15); PGPI (SEQ.ID.NO.16); GLPGPIG (SEQ.ID.NO.17); GPIGP* (SEQ.ID.NO.18); GPIGP (SEQ.ID.NO.19); PIGP (SEQ.ID.NO.20) and mixtures thereof. 38. The method of claim 37, wherein said peptide is at least four amino acids in length. 39. The peptide of claim 1 wherein the period of time is selected from the group consisting of at least 48 hours, at least 1 week, at least 3 weeks, at least 6 weeks, at least 9 weeks and at least 12 weeks. 40. The composition of claim 29 wherein the period of time is selected from the group consisting of at least 48 hours, at least 1 week, at least 3 weeks, at least 6 weeks, at least 9 weeks and at least 12 weeks.

Details for Patent 9,133,236

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-05-03